Related Experiment Videos
Dmt and opioid peptides: a potent alliance
Sharon D Bryant1, Yunden Jinsmaa, Severo Salvadori
1Peptide Neurochemistry, LCBRA, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA. bryant2@niehs.nih.gov
Biopolymers
|May 27, 2003
Summary
The Dmt-Tic pharmacophore significantly advanced opioid research, yielding potent delta-opioid receptor antagonists and agonists. Subtle structural changes and molecular studies reveal its versatility for future pain management therapies.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Neuroscience
Background:
- The Dmt (2',6'-dimethyl-L-tyrosine)-Tic pharmacophore revolutionized opioid ligand design.
- Its incorporation into opioid molecules led to potent delta-opioid receptor antagonists and unique analogues.
Purpose of the Study:
- To review the crucial role of the Dmt residue in developing opioid peptides with high receptor affinity and bioactivity.
- To discuss structural modifications, receptor interactions, and therapeutic potential of Dmt-Tic compounds.
Main Methods:
- Review of existing literature on Dmt-Tic pharmacophore in opioid research.
- Analysis of structural studies including X-ray diffraction and molecular modeling.
- Examination of in vivo behavior and receptor binding affinities (K(i) ≤ 1 nM).
Main Results:
- Dmt-Tic pharmacophore yields potent delta-opioid receptor antagonists and agonists.
- Subtle structural changes induce metamorphosis between antagonist and agonist activity.
- Dmt residue exhibits promiscuity, leading to mu-agonism in certain derivatives.
Conclusions:
- The Dmt-Tic pharmacophore is pivotal in advancing opioid research and drug discovery.
- Structural insights from X-ray diffraction and modeling aid in designing targeted opioid ligands.
- Dmt-Tic compounds show promise for therapeutic applications, including cancer pain management.